TABLE 2.

AEs.

	200 mg BID (n = 10)	300 mg BID (n = 10)	400 mg BID (n = 10)	500 mg BID (n = 10)	SHR7280 total (n = 40)	Placebo (n = 8)
Any AE	9 (90.0)	10 (100)	10 (100)	10 (100)	39 (97.5)	7 (87.5)
Reproductive system and breast disorders
Oligomenorrhoea	8 (80.0)	10 (100)	10 (100)	10 (100)	38 (95.0)	0
Heavy menstrual bleeding	1 (10.0)	2 (20.0)	0	1 (10.0)	4 (10.0)	0
Investigations
Alanine aminotransferase increased	2 (20.0)	3 (30.0)	0	3 (30.0)	8 (20.0)	2 (25.0)
Urine leukocyte esterase positive	2 (20.0)	2 (20.0)	2 (20.0)	2 (20.0)	8 (20.0)	2 (25.0)
Neutrophil count decreased	0	2 (20.0)	3 (30.0)	2 (20.0)	7 (17.5)	0
Blood thyroid stimulating hormone increased	1 (10.0)	1 (10.0)	4 (40.0)	0	6 (15.0)	0
White blood cell count decreased	0	1 (10.0)	2 (20.0)	2 (20.0)	5 (12.5)	0
White blood cells urine positive	1 (10.0)	1 (10.0)	2 (20.0)	0	4 (10.0)	1 (12.5)
Estradiol decreased	2 (20.0)	1 (10.0)	0	1 (10.0)	4 (10.0)	0
Thyroxine free decreased	2 (20.0)	1 (10.0)	0	1 (10.0)	4 (10.0)	0
Gastrointestinal disorders
Abdominal pain	2 (20.0)	2 (20.0)	1 (10.0)	0	5 (12.5)	4 (50.0)
Diarrhea	2 (20.0)	1 (10.0)	1 (10.0)	0	4 (10.0)	1 (12.5)
Infections and infestations
Bacterial vulvovaginitis	0	3 (30.0)	0	2 (20.0)	5 (12.5)	0
Asymptomatic bacteriuria	2 (20.0)	2 (20.0)	0	0	4 (10.0)	3 (37.5)
Blood and lymphatic system disorders
Anemia	1 (10.0)	1 (10.0)	2 (20.0)	0	4 (10.0)	0

Data are n (%). AEs occurred in ≥10% of total participants who received SHR7280 are listed.